Asset profile

Ipilimumab

Monoclonal antibody

ApprovedCTLA-4
Approvedregulatory verdict

Evidence outlook

Approved — Non-Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

Upcoming events

(27 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (4)
October 2026 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-10 · NCT04933903 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (3)
Phase 2Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder, Non-urothelial Upper Tract, Penile Cancer …Active not recruiting
Est. primary completion 2026-12-30 · NCT03333616 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT05597800 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT03297606 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (12)
February 2027 (2)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-02-05 · NCT06946797 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02-28 · NCT06047379 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (1)
Phase 3Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8Active not recruiting
Est. primary completion 2027-03-31 · NCT03391869 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04-27 · NCT06364917 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04-28 · NCT05715229 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone, Malignant Solid Neoplasm …Active not recruiting
Est. primary completion 2027-04-30 · NCT03449108 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (1)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-06 · NCT03546686 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10-15 · NCT05012254 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (4)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT06362369 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT02696993 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT04940299 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (1)
December 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-30 · NCT06492421 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (3)
September 2029 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09 · NCT07563738 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2029 (1)
Phase 1/2Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer, Ovary Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer …Recruiting
Est. primary completion 2029-10-30 · NCT05187338 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2029 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-11-02 · NCT04665206 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (4)
March 2030 (1)
Phase 2Lung Cancer - Non Small CellRecruiting
Est. primary completion 2030-03-31 · NCT06926790 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2030 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-06-25 · NCT07603856 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2030 (1)
Phase 1/2Triple-Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2030-09 · NCT07762703 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2030 (1)
Phase 2/3Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 …Active not recruiting
Est. primary completion 2030-12-12 · NCT04929041 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (1)
January 2031 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2031-01-01 · NCT03815890 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (1)
July 2032 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-07-31 · NCT07355205 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2040 (1)
February 2040 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2040-02-28 · NCT07770100 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.

Educational data tool. Grades describe evidence quality, not investment merit.